A traditional Chinese medicine composition and a medicine preparation for reducing blood uric acid

Abstract

The present application relates to the technical field of medicine and health, and particularly relates to a traditional Chinese medicine composition and a medicine preparation for reducing blood uric acid. The traditional Chinese medicine composition comprises the following components in parts by weight: Alisma 10-50 parts, Atractylodes 5-40 parts, Coicis Semen 20-60 parts, Corn Silk 10-50 parts, Smilax 5-40 parts, and Chaenomeles 5-25 parts. The traditional Chinese medicine composition provided by the present application has reasonable structure, appropriate compatibility, no obvious toxic side effects, and can be used for hyperuricemia, preventing and treating gout and kidney damage while reducing blood uric acid, and can comprehensively regulate the whole body organs, enhance the functions of spleen, liver, kidney and other organs, and has the effects of invigorating the spleen, promoting water and removing dampness, removing turbidity and the like.

Description

TECHNICAL FIELD

[0001] The present application relates to the field of medical health technology, and particularly relates to a traditional Chinese medicine composition and a blood uric acid reducing pharmaceutical preparation. BACKGROUND

[0002] Hyperuricemia (HUA) is a purine metabolic disease caused by excessive production or insufficient excretion of blood uric acid (SUA), which can induce gout and is closely related to type 2 diabetes, hypertension, arteriosclerosis and coronary heart disease. Excessive intake of high purine food, uric acid excretion disorder and excessive uric acid production can all cause blood purine to rise, and then cause metabolic abnormalities to cause uric acid to rise. Long-term hyperuricemia can cause acute and chronic gouty arthritis, gout stone deposition, chronic renal insufficiency, etc. According to the pathological mechanism of hyperuricemia, it can be attributed to "arthralgia" in traditional Chinese medicine, which belongs to the category of "endogenous dampness", and it is believed that "spleen and kidney deficiency, dampness and turbidity" is the basic pathogenesis.

[0003] Modern medicine treats hyperuricemia by using drugs such as allopurinol, febuxostat and benzbromarone to inhibit uric acid synthesis and promote uric acid excretion, but such drugs cannot prevent the occurrence of adverse results such as gouty arthritis and kidney damage in the long run. Therefore, it is of great significance to provide a traditional Chinese medicine preparation for treating hyperuricemia, which can reduce blood uric acid and prevent and treat gout and kidney damage. SUMMARY

[0004] In order to solve the above technical problems, the present application provides a traditional Chinese medicine composition and a blood uric acid reducing pharmaceutical preparation. The traditional Chinese medicine composition has reasonable structure, appropriate compatibility, no obvious toxic and side effects, and can be used for hyperuricemia to prevent and treat gout and kidney damage while reducing blood uric acid.

[0005] In the first aspect, the present application provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0006] 10-50 parts of alisma orientalis, 5-40 parts of atractylodes, 20-60 parts of coix seed, 10-50 parts of corn silk, 5-40 parts of smilax, and 5-25 parts of chaenomeles.

[0007] The alisma orientalis can be 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, etc.

[0008] The atractylodes can be 5 parts, 10 parts, 20 parts, 30 parts, 40 parts, etc.

[0009] The coix seed can be 20 parts, 30 parts, 40 parts, 50 parts, 60 parts, etc.

[0010] The corn silk can be 10 parts, 20 parts, 30 parts, 40 parts, 50 parts, etc.

[0011] The alisma can be 5 parts, 10 parts, 20 parts, 30 parts, 40 parts, etc.

[0012] The papaya can be 5 parts, 10 parts, 15 parts, 20 parts, 25 parts, etc.

[0013] The traditional Chinese medicine composition provided by the application is based on the overall consideration, takes the principle of syndrome differentiation and treatment, starts from the pathogenesis of hyperuricemia, adopts the treatment method of "removing dampness and discharging turbidity", can prevent and treat gout, kidney damage, etc. while reducing blood uric acid, achieves the purpose of treating both the symptoms and the root cause and has less adverse reactions.

[0014] As a preferred technical solution of the application, the traditional Chinese medicine composition comprises the following components in parts by weight:

[0015] Alisma 20-40 parts, white atractylodes 10-30 parts, coix seed 30-50 parts, corn silk 20-40 parts, alisma 10-30 parts, papaya 10-20 parts.

[0016] As a preferred technical solution of the application, the traditional Chinese medicine composition comprises the following components in parts by weight:

[0017] Alisma 30 parts, white atractylodes 20 parts, coix seed 40 parts, corn silk 30 parts, alisma 20 parts, papaya 15 parts.

[0018] The compatibility mechanism of the traditional Chinese medicine composition provided by the application is as follows:

[0019] Alisma is the dry tuber of Alisma orientalis (Sam.) Juzep. of Alismataceae, mainly produced in Fujian, Sichuan, Jiangxi and other places, has the effects of removing water and dampness, discharging heat, resolving turbidity and diuresis; white atractylodes: sweet and bitter in taste, warm in nature, has the effects of invigorating the spleen and tonifying qi, drying dampness and water, ascending clear and descending turbid; coix seed: sweet and bland in taste, cool in nature, has the effects of removing water and dampness, invigorating the spleen to stop diarrhea, removing impediment, draining pus, resolving toxicity and resolving mass; corn silk: sweet and bland in taste, flat in nature, has the effects of diuresis and swelling, clearing liver and gallbladder; alisma: sweet and bland in taste, flat in nature, has the effects of resolving toxicity, removing dampness and unblocking joints; papaya: sour in taste, warm in nature, has the effects of relaxing sinews and promoting digestion. The traditional Chinese medicine composition provided by the application takes alisma as the monarch, and is combined with white atractylodes, coix seed, corn silk, alisma and papaya, reduces blood uric acid from multiple targets and multiple dimensions, has the effects of resolving dampness and turbidity, invigorating the spleen and diuresis. From the perspective of modern medicine, the main mechanism is to inhibit uric acid synthesis, improve kidney function and reduce inflammatory stress response.

[0020] The prescription starts from the overall concept of traditional Chinese medicine, can regulate the whole body organs, blood vessels and blood flow in all directions, enhances the functions of the spleen, liver, kidney and other organs, has the effects of invigorating the spleen, removing water and dampness and removing turbidity. Moreover, the prescription and the dosage are reasonable, can make up for the efficacy of single drug, and achieve the ideal effect.

[0021] In a second aspect, the present application provides use of the traditional Chinese medicine composition of the first aspect in the preparation of a medicine for reducing blood uric acid.

[0022] In a third aspect, the present application provides a medicine for reducing blood uric acid, which comprises an effective component of the traditional Chinese medicine composition of the first aspect.

[0023] The effective component of the traditional Chinese medicine composition of the present application can be extracted by the preparation method of the fourth aspect.

[0024] The medicine preparation provided by the present application has the effects of reducing blood uric acid and relieving kidney damage, and can be used for treating hyperuricemia.

[0025] As a preferred technical solution of the present application, the medicine preparation further comprises an excipient.

[0026] The excipient can be selected from binders, fillers, disintegrants, lubricants, emulsifiers, flavoring agents, solubilizers, solubilizers, colorants, etc. The present application does not specially limit the specific types of the excipient, and the person skilled in the art can select according to the actual needs.

[0027] As a preferred technical solution of the present application, the dosage form of the medicine preparation is granules, tablets, capsules, oral liquid or decoction, oral liquid such as syrup, and preferably granules.

[0028] In a fourth aspect, the present application provides a preparation method of the medicine preparation of the third aspect, which comprises the following steps:

[0029] (1) water extraction of each raw material to obtain a water extract;

[0030] (2) preparing the water extract into the dosage form of the medicine preparation.

[0031] As a preferred technical solution of the present application, the water used in step (1) is 6-10 times the mass of the medicinal material, for example, 6 times, 7 times, 8 times, 9 times, 10 times, etc.

[0032] As a preferred technical solution of the present application, the water extraction method of step (1) is: decocting at least twice, each time for 0.5-2h (for example, 0.5h, 1h, 1.5h, 2h, etc.), and filtering.

[0033] As a preferred technical solution of the present application, the step (2) comprises the following steps: concentrating the water extract into a extract, and granulating after mixing with an excipient.

[0034] After granulation, the present application still needs to be dried to obtain the medicine preparation, which is packed, sealed and stored.

[0035] As a preferred technical solution of the present application, the mass ratio of the excipient to the extract in step (2) is 3-5:1, for example, 3:1, 4:1, 5:1, etc.

[0036] As a preferred technical solution of the present application, the excipient in step (2) is a mixture of dextrin and sucrose, preferably the mass ratio of the dextrin to the sucrose is 1:3.

[0037] As a specific embodiment of the present application, the preparation method comprises the following steps:

[0038] (1) mixing raw materials, decocting with water for at least 2 times, each time for 0.5-2h, wherein the amount of water is 6-10 times the mass of medicinal materials, to obtain water extract;

[0039] (2) combining and concentrating the water extract into extract, and mixing with excipient (a mixture of dextrin and sucrose) to granulate, wherein the mass ratio of the excipient to the extract is 3-5:1.

[0040] The technical solution provided by the embodiment of the present application has the following advantages compared with the prior art:

[0041] 1. The traditional Chinese medicine composition provided by the present application uses Alisma orientalis (S. et S.) Juzep, Atractylodes macrocephala Koidz, Coix lachryma-jobi L., Zea mays L., Smilax glabra Roxb and Chaenomelis fruit to be scientifically matched, starting from the pathogenesis of hyperuricemia, using the treatment method of "removing dampness and discharging turbidity", which can reduce blood uric acid, prevent and treat gout and kidney damage, and can also comprehensively regulate the whole body organs, enhance the functions of spleen, liver and kidney, and has the effects of invigorating the spleen, removing dampness and promoting water metabolism, and discharging turbidity.

[0042] 2. The pharmaceutical preparation provided by the present application has simple prescription and simple manufacturing process, and has no obvious toxic and side effects, and can be used for hyperuricemia, and has the beneficial effect of reducing blood uric acid. DETAILED DESCRIPTION

[0043] In order to more clearly understand the above-mentioned purposes, features and advantages of the present application, the solutions of the present application will be further described below. It should be noted that the embodiments of the present application and the features in the embodiments can be combined with each other without conflict.

[0044] In the following description, many specific details are set forth in order to provide a thorough understanding of the present application, but the present application can also be implemented in other ways different from those described herein; obviously, the embodiments in the specification are only a part of the embodiments of the present application, not all the embodiments.

[0045] Embodiment 1

[0046] The present embodiment provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0047] Alisma orientale 50 parts, Atractylodes macrocephala 5 parts, Coix seed 60 parts, corn silk 10 parts, Smilax glabra 40 parts, Chaenomeles speciosa 5 parts.

[0048] The embodiment also provides a granule for reducing blood uric acid, and a preparation method thereof is as follows:

[0049] (1) According to the proportion of the traditional Chinese medicine composition provided in the embodiment, Alisma orientale, Atractylodes macrocephala, Coix seed, corn silk, Smilax glabra and Chaenomeles speciosa are taken, mixed, and then decocted twice with water, 10 times the mass of water is added for the first time and decocted for 2 h, 6 times the mass of water is added for the second time and decocted for 0.5 h, and the decoction is combined and filtered;

[0050] (2) The filtrate is concentrated into extract, auxiliary materials (a mixture of dextrin and sucrose, the mass ratio of dextrin to sucrose is 1:3) are added into the extract, the mass ratio of the auxiliary materials to the extract is 3:1, and the mixture is fully stirred and uniformly distributed, and then the granule is prepared by using a traditional Chinese medicine granule preparation machine, and the granule is dried in a 60°C oven, so that the granule is obtained.

[0051] Embodiment 2

[0052] The embodiment provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0053] Alisma orientale 10 parts, Atractylodes macrocephala 40 parts, Coix seed 20 parts, corn silk 50 parts, Smilax glabra 5 parts and Chaenomeles speciosa 25 parts.

[0054] The embodiment also provides a granule for reducing blood uric acid, and a preparation method thereof is as follows:

[0055] (1) According to the proportion of the traditional Chinese medicine composition provided in the embodiment, Alisma orientale, Atractylodes macrocephala, Coix seed, corn silk, Smilax glabra and Chaenomeles speciosa are taken, mixed, and then decocted twice with water, 10 times the mass of water is added for the first time and decocted for 2 h, 6 times the mass of water is added for the second time and decocted for 0.5 h, and the decoction is combined and filtered;

[0056] (2) The filtrate is concentrated into extract, auxiliary materials (a mixture of dextrin and sucrose, the mass ratio of dextrin to sucrose is 1:3) are added into the extract, the mass ratio of the auxiliary materials to the extract is 3:1, and the mixture is fully stirred and uniformly distributed, and then the granule is prepared by using a traditional Chinese medicine granule preparation machine, and the granule is dried in a 60°C oven, so that the granule is obtained.

[0057] Embodiment 3

[0058] The embodiment provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0059] Alisma orientale 40 parts, Atractylodes macrocephala 10 parts, Coix seed 50 parts, corn silk 20 parts, Smilax glabra 30 parts and Chaenomeles speciosa 10 parts.

[0060] The embodiment also provides a granule for reducing blood uric acid, and a preparation method thereof is as follows:

[0061] (1) according to the ratio of the traditional Chinese medicine composition provided in this embodiment, take alisma, atractylodes, coix seed, corn silk, smilax and papaya, mix and add water to decoct twice, add 10 times the mass of water to decoct for 1h the first time, add 6 times the mass of water to decoct for 1h the second time, combine the decoction and filter;

[0062] (2) the filtrate is concentrated into an extract, auxiliary materials (a mixture of dextrin and sucrose, the mass ratio of dextrin and sucrose is 1:3) are added to the extract, the mass ratio of auxiliary materials and extract is 4:1, fully stir and uniformly, then granules are prepared by a traditional Chinese medicine granulator, dried in a 60℃ oven, and the granules are obtained.

[0063] Example 4

[0064] This embodiment provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0065] 20 parts of alisma, 30 parts of atractylodes, 30 parts of coix seed, 40 parts of corn silk, 10 parts of smilax and 20 parts of papaya.

[0066] This embodiment also provides a granule for reducing blood uric acid, and the preparation method thereof is the same as that in example 3.

[0067] Example 5

[0068] This embodiment provides a traditional Chinese medicine composition, which comprises the following components in parts by weight:

[0069] 30 parts of alisma, 20 parts of atractylodes, 40 parts of coix seed, 30 parts of corn silk, 20 parts of smilax and 15 parts of papaya.

[0070] This embodiment also provides a granule for reducing blood uric acid, and the preparation method thereof is the same as that in example 3.

[0071] Experimental example

[0072] This experimental example explores the efficacy of the granule for reducing blood uric acid prepared by the present application.

[0073] 1. Experimental materials

[0074] Experimental animals: 8-week-old healthy SPF level SD male rats were provided by Beijing Huafukang Biotechnology Co., Ltd., license number: SCXK (Shanghai) 2018-0016. During the feeding process, 5 rats were fed in each cage, the indoor temperature and humidity were kept constant (temperature 20-20℃, humidity 40%-60%), the day-night cycle was 12h / 12h, and the rats were free to drink water and eat food.

[0075] Experimental drugs: potassium oxonate, adenine solution, 0.5% carboxymethylcellulose sodium solution, example granule for reducing blood uric acid, allopurinol, etc.

[0076] 2. Experimental method

[0077] 2.1 Grouping and administration

[0078] 10 rats were randomly selected as the normal control group, and the remaining rats were administered with oxypurinol potassium and adenine solution at 1.5 g / kg and 0.1 g / kg respectively by gavage once a day. The normal control group was administered with the same volume of 0.5% sodium carboxymethyl cellulose solution. The increase in serum uric acid (SUA) level was used as the success criterion for modeling hyperuricemia.

[0079] The hyperuricemia model rats were randomly divided into a model control group, a high-dose group of Example 5 (0.72 g of granules per 100 g of rats by gavage), a medium-dose group of Example 5 (0.36 g of granules per 100 g of rats by gavage), a low-dose group of Example 5 (0.18 g of granules per 100 g of rats by gavage), and an allopurinol group (positive drug group) using a random number table. The administration groups were administered with an aqueous solution of granules every day by gavage, the positive drug group was administered with an aqueous solution of allopurinol by gavage, the normal control group and the model control group were administered with the same dose of pure water by gavage, and the administration lasted for 21 days.

[0080] To maintain a stable high blood uric acid state, the remaining groups were administered with a mixture of 1.5 g / kg oxypurinol potassium and 0.1 g / kg adenine solution by gavage every other day during the administration period, except for the normal control group.

[0081] 2.2 Detection of blood uric acid and other biochemical indicators

[0082] After the last administration, the rats in each group were fasted for 12 h without water, weighed, and then anesthetized by intraperitoneal injection of alflutin, blood was taken from the abdominal aorta, centrifuged at 4000 rpm for 15 min, and the supernatant was stored at -80°C. Then the bilateral kidneys, liver and spleen were dissected, weighed and recorded on an electronic balance after removing the surrounding tissues, and the organ coefficients were calculated, the formula being: organ coefficient = organ mass (mg) / body mass (g).

[0083] The prepared serum was dissolved at room temperature, and the absorbance was measured by an enzyme marker according to the kit instructions. The serum uric acid (SUA), urea nitrogen (BUN), creatinine (SCr) levels, xanthine oxidase (XOD), glutamic-pyruvic transaminase (ALT), and glutamic-oxalacetic transaminase (AST) activities were calculated according to the formula.

[0084] 2.3 Statistical analysis

[0085] The collected data were analyzed by SPSS 26.0 statistical software, and the experimental data were expressed as The single factor ANOVA test was used for comparison between groups, and the LSD (assuming equal variance) or Dunnett T3 (not assuming equal variance) was used for further pairwise comparison. p<0.05 was considered statistically significant.

[0086] 3. Experimental results

[0087] 3.1 The influence of granules on SUA level of rats

[0088] Table 1 SUA concentration of rats in each group n = 6

[0089] Group SUA (μmol / L) Normal control group 34.24±13.68 Model control group 211.92 ± 51.41 ## ]] Example 5 high dose group 68.96 ± 32.77 ** ]] Example 5 middle dose group 53.65 ± 13.66 ** ]] Example 5 low dose group 48.88 ± 21.94 ** ]] Allopurinol group 36.24 ± 18.84 ** ]]

[0090] Note a: compared with the normal group, ##p<0.01; note b: compared with the model group, **p<0.01.

[0091] It can be found from Table 1 that the SUA level of the model control group of rats is significantly increased compared with the normal control group, indicating that the hyperuricemia model rats are successfully modeled. Compared with the model control group, the SUA level of the high, medium and low dose groups of Example 5 and the allopurinol group is significantly reduced, indicating that the granules prepared from the traditional Chinese medicine composition of the application can reduce the blood uric acid of the hyperuricemia model rats, and the low dose group has the best effect on reducing the blood uric acid level.

[0092] 3.2 The influence of granules on kidney coefficient, BUN and SCr level of rats

[0093] Table 2 kidney coefficient, BUN and SCr level of rats in each group n = 6

[0094] Group Kidney coefficient BUN (mmol / L) SCr (μmol / L) Normal control group 5.52±0.27 9.13±0.88 47.00±8.91 Model control group 8.83 ± 1.33 ## ]] 12.96 ± 0.98 ## ]] 62.18 ± 10.10 ## ]] Example 5 high dose group 8.14±0.47 12.50 ± 1.11 ** ]] 54.26±5.19 Example 5 middle dose group 8.28±0.83 10.44 ± 1.04 ** ]] 53.87±9.73 Example 5 low dose group 7.77 ± 0.68 & ]] 9.98 ± 0.92 ** ]] 48.47 ± 3.96 ** ]] Allopurinol group 6.78±0.18** 9.86 ± 0.65 ** ]] 52.07 ± 9.48 & ]]>

[0095] Note a: compared with the normal group, ##p<0.01; note b: compared with the model group, **p<0.01; note c: compared with the model group, &p<0.05.

[0096] It can be found from Table 2 that the kidney coefficient, BUN and SCr level of the model control group of rats is significantly increased compared with the normal control group, indicating that the modeling drug not only increases the blood uric acid but also causes kidney damage in rats. Compared with the model control group, the kidney coefficient of the low dose group of Example 5 and the allopurinol group is significantly reduced, the BUN level of the high, medium and low dose groups of Example 5 and the allopurinol group is significantly decreased, and the SCr level of the low dose group of Example 5 and the allopurinol group is significantly decreased, indicating that the granules prepared from the traditional Chinese medicine composition of the application can inhibit the kidney swelling caused by hyperuricemia and reduce the kidney damage.

[0097] 3.3 The influence of granules on XOD activity of rats

[0098] Table 3 XOD activity of rats in each group n = 6

[0099] Group XOD (U / L) Normal control group 15.88±1.29 Model control group 21.21 ± 2.25 ## ]] Example 5 high dose group 20.54±2.11 Example 5 middle dose group 20.40±1.63 Example 5 low dose group 17.37 ± 3.36 ** ]] Allopurinol group 16.9 ± 2.61 ** ]]

[0100] Note a: Compared with the normal group, ##p<0.01; Note b: Compared with the model group, **p<0.01.

[0101] Xanthine oxidase is an enzyme with low specificity, which can catalyze hypoxanthine to generate xanthine, and then generate uric acid, and can also directly catalyze xanthine to generate uric acid. It can be found from Table 3 that compared with the normal control group, the xanthine oxidase activity of the model control group of rats is significantly increased, thereby causing the blood uric acid of rats to be significantly increased. Compared with the model control group, the xanthine oxidase activity of the low-dose group of Example 5 and the allopurinol group is significantly reduced, indicating that the granules prepared from the traditional Chinese medicine composition have a certain inhibitory effect on xanthine oxidase, which may be one of the mechanisms of reducing blood uric acid.

[0102] 3.4 The influence of the granules on the spleen coefficient, liver coefficient, ALT and AST activity of rats is shown in Table 4:

[0103] Table 4 Spleen coefficient, liver coefficient, ALT and AST activity of rats in each group n=6

[0104] Group Spleen coefficient Liver coefficient ALT (U / L) AST (U / L) Normal control group 24.70±1.51 1.63±0.19 12.89±3.44 11.47±1.94 Model control group 25.21±1.21 2.08 ± 0.30 # ]] 13.71±3.48 11.58±2.11 Example 5 high dose group 25.26±1.61 2.11±0.40 13.29±3.00 11.35±2.39 Example 5 middle dose group 26.07±1.71 2.03±0.31 14.58±3.12 10.47±1.55 Example 5 low dose group 25.31±1.21 2.21±0.42 14.12±0.84 10.48±3.28 Allopurinol group 24.43±0.69 1.98±0.17 14.48±0.97 11.88±2.37

[0105] Note: Compared with the normal group, #p<0.05.

[0106] It can be found from Table 4 that the spleen coefficient, liver coefficient, ALT activity and AST activity of rats in the model control group, the high-dose, medium-dose and low-dose groups of Example 5 and the allopurinol group have no significant difference, indicating that the granules prepared from the traditional Chinese medicine composition have good safety and no adverse reactions.

[0107] In summary, it can be found that the granules prepared from the traditional Chinese medicine composition can be used for hyperuricemia, prevent and treat gout and kidney damage while reducing blood uric acid, have no toxic side effects, and can comprehensively regulate the whole body organs, blood vessels and blood flow, enhance the functions of spleen, liver, kidney and other organs, and have the effects of invigorating the spleen, promoting water and removing dampness, removing turbidity and the like.

[0108] It has to be noted that, in the present document, the terms "first", "second", etc. merely serve the purpose of distinguishing between two entities or operations, without necessarily requiring or implying any actual relationship or order between these entities or operations. Moreover, the terms "comprising", "containing" or any other transitional term, do not exclude other matters besides the one(s) named, nor do they preclude the presence or addition of one or more other elements or interventions. Without more limitations, an element defined by the phrase "comprising a... " does not exclude the presence of additional identical elements in the process, method, article, or apparatus including the one(s) defined by the phrase "comprising a... ".

[0109] The foregoing is considered as illustrative only of the principles of the application. Numerous modifications and changes will readily occur to those skilled in the art, and the generic principles defined herein can be applied to other embodiments without departing from the spirit or scope of the application. Accordingly, the scope of the application is indicated by the appended claims rather than by the foregoing description, and all changes which come within the meaning and range of equivalency of the claims are intended to be embraced therein.

Claims

1. A traditional Chinese medicine composition for reducing blood uric acid, characterized in that, The traditional Chinese medicine composition is composed of components in the following weight proportions: Alisma 10-50 parts, Bai-Zhu 5-40 parts, Yiyiren 20-60 parts, corn silk 10-50 parts, Tu-Fuling 5-40 parts, and Muguai 5-25 parts.

2. The traditional Chinese medicine composition for reducing blood uric acid according to claim 1, characterized in that, The traditional Chinese medicine composition is composed of components in the following weight proportions: Alisma 20-40 parts, Bai-Zhu 10-30 parts, Yiyiren 30-50 parts, corn silk 20-40 parts, Tu-Fuling 10-30 parts, and Muguai 10-20 parts.

3. The traditional Chinese medicine composition for reducing blood uric acid according to claim 2, characterized in that, The traditional Chinese medicine composition is composed of components in the following weight proportions: Alisma 30 parts, Bai-Zhu 20 parts, Yiyiren 40 parts, corn silk 30 parts, Tu-Fuling 20 parts, and Muguai 15 parts.

4. Use of the traditional Chinese medicine composition for lowering blood uric acid according to any one of claims 1-3 in the preparation of a medicine for lowering blood uric acid.

5. A pharmaceutical preparation for reducing blood uric acid, characterized by, The effective component in the medicine preparation is the effective component of the traditional Chinese medicine composition according to any one of claims 1-3.

6. The pharmaceutical preparation according to claim 5, characterized in that, The medicine preparation further comprises an excipient.

7. The pharmaceutical preparation according to claim 5 or 6, characterized in that, The dosage form of the medicine preparation is granules, tablets, capsules, or oral liquid.

8. The pharmaceutical preparation according to claim 7, characterized in that The dosage form of the medicine preparation is granules.

9. A process for the preparation of a pharmaceutical preparation as claimed in any one of claims 5 to 8, characterized in that, The preparation method comprises the following steps: (1) water extraction of each raw material to obtain a water extract; (2) preparation of the water extract into the dosage form of the medicine preparation.

10. The method of claim 9, wherein, The amount of water used in the water extraction of step (1) is 6-10 times the mass of the medicinal material; and / or, step (2) comprises the following steps: concentration of the water extract into an extract, mixing with an excipient, and granulation.

11. The method of claim 10, wherein, The method of water extraction of step (1) is decoction for at least 2 times, each time for 0.5-2 h, and filtration; and / or, the mass ratio of the excipient to the extract of step (2) is 3-5:1; and / or, the excipient of step (2) is a mixture of dextrin and sucrose.